A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia.

Trial Profile

A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2016

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Piperacillin/tazobactam
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms VECTOR
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 28 Jan 2014 According to the ClinicalTrials.gov record, the status changed from recruiting to discontinued.
    • 08 Jul 2013 Planned End Date changed from 1 Jan 2016 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 01 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top